{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T05:58:14Z","timestamp":1722923894652},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:p>Individuals with a history of injecting drugs have a high prevalence of chronic hepatitis C (HCV) infection. Many have a history of opioid use disorder (OUD). Despite novel treatments with improved efficacy and tolerability, treatment is limited in the group. A faculty of experts shared insights from clinical practice to develop an HCV care-readiness model. Evidence and expert knowledge was collected. Ten experts developed a model of three factors (with measures): \u2018healthcare engagement\u2019, \u2018guidance\u2019 and \u2018place\u2019. Overall, 40\u201390% of individuals with OUD engage with drug treatment services. Ten of 12 HCV guidelines provided specific advice for the OUD population. Ten of 12 OUD care guidelines provided useful HCV care advice. In 11 of 12 cases, location of HCV\/drug treatment care was in different places. This readiness assessment shows that there are important limitations to successful HCV care in OUD. Specific actions should be taken: maintain\/increase access to OUD treatment services\/opioid agonist therapy, updating HCV guidance, locate care in the same place and allow wider prescribing of anti HCV medicines.<\/jats:p>","DOI":"10.1097\/meg.0000000000000962","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T22:46:32Z","timestamp":1505342792000},"page":"1206-1214","source":"Crossref","is-referenced-by-count":9,"title":["Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model"],"prefix":"10.1097","volume":"29","author":[{"given":"Nat","family":"Wright","sequence":"first","affiliation":[{"name":"Transform Research Alliance, Huddersfield University, Huddersfield"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Reimer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Centre for Interdisciplinary Addiction Research, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Somaini","sequence":"additional","affiliation":[{"name":"Addiction Treatment Centre, Biella"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Roncero","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Addiction and Dual Diagnosis Unit, Vall d\u2019Hebron University Hospital, Biomedical Research Center Network of Mental Health, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Icro","family":"Maremmani","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Santa Chiara University Hospital, University of Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Adult Psychiatry and Clinical Pharmacology, Public Assistance Marseillie Hospital, Sainte Marguerite Hospital, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Krajci","sequence":"additional","affiliation":[{"name":"Department of Substance Use Disorder Treatment, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Littlewood","sequence":"additional","affiliation":[{"name":"Applied Strategic, London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"D\u2019Agnone","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Human Sciences, Institute of Brain Behaviour and Mental Health, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannu","family":"Alho","sequence":"additional","affiliation":[{"name":"Abdominal Center, Department of Medicine, University Hospital and University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Rolland","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, University Hospital of Lille, Lille"},{"name":"Pharmacology, University Hospital of Lille, Lille"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"e103345","DOI":"10.1371\/journal.pone.0103345","article-title":"Hepatitis C virus infection epidemiology among people who inject drugs in europe: a systematic review of data for scaling up treatment and prevention","volume":"9","author":"Wiessing","year":"2014","journal-title":"PLoS One"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.drugpo.2014.08.014","article-title":"Prevention, treatment and care of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Bruggmann","year":"2015","journal-title":"Int J Drug Policy"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.drugpo.2015.04.015","article-title":"An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: structural barriers and public health potential","volume":"26","author":"Perlman","year":"2015","journal-title":"Int J Drug Policy"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1186\/1471-2334-14-S6-S16","article-title":"A systematic review of hepatitis C virus treatment uptake among people who inject drugs in the European Region","volume":"14","author":"Lazarus","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000179","article-title":"The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention","volume":"10","author":"Martin","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of opioid-use disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N Engl J Med"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Grebely","year":"2015","journal-title":"Int J Drug Policy"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1747-597X-8-35","article-title":"Qualitative investigation of barriers to accessing care by people who inject drugs in Saskatoon, Canada: perspectives of service providers","volume":"8","author":"Lang","year":"2013","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/MEG.0000000000000855","article-title":"Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment","volume":"29","author":"Roncero","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.drugpo.2015.07.004","article-title":"Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): a systematic review and meta-analysis","volume":"26","author":"Smith","year":"2015","journal-title":"Int J Drug Policy"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2010.03.015","article-title":"The natural history of hepatitis C infection acquired through injection drug use: eta-analysis and meta-regression","volume":"53","author":"John-Baptiste","year":"2010","journal-title":"J Hepatol"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation","volume":"65","author":"Martin","year":"2016","journal-title":"J Hepatol"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(10)60232-2","article-title":"HIV prevention, treatment, and care services for people who inject drugs\u202f: a systematic review of global, regional, and national coverage","volume":"375","author":"Mathers","year":"2010","journal-title":"Lancet"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"46","author":"Cacoub","year":"2014","journal-title":"Dig Liver Dis"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/ajt.12714","article-title":"Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: \u2018a flood of opportunity\u2019","volume":"14","author":"Gane","year":"2014","journal-title":"Am J Transplant"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","article-title":"Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine","volume":"63","author":"Lalezari","year":"2015","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"R22-20230916","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R26-20230916","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2334-12-178","article-title":"Hepatitis C prevalence in Denmark \u2013 an estimate based on multiple national registers","volume":"12","author":"Christensen","year":"2012","journal-title":"BMC Infect Dis"},{"key":"R34-20230916","first-page":"191","article-title":"HIV, hepatitis B und C bei injizierenden Drogengebrauchen den in Deutschland \u2013 Ergebnisse der DRUCK-Studie des RKI [HIV, hepatitis B and C injecting drug use in Germany-Results of the DRUCKStudie of the RKI]","volume":"June","year":"2015","journal-title":"Epidemiol Bull RKI"},{"key":"R36-20230916","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/jmv.23370","article-title":"Hepatitis C virus infection among drug addicts in Italy","volume":"84","author":"Stroffolini","year":"2012","journal-title":"J Med Virol"},{"key":"R37-20230916","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jsat.2013.02.001","article-title":"Italy\u2019s electronic health record system for opioid agonist treatment","volume":"45","author":"Serpelloni","year":"2013","journal-title":"J Subst Abuse Treat"},{"key":"R43-20230916","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2471\/BLT.12.111054","article-title":"Methadone maintenance treatment in Spain: the success of a harm reduction approach","volume":"91","author":"Torrens","year":"2013","journal-title":"Bull World Health Organ"},{"key":"R44-20230916","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/00365521.2014.990505","article-title":"The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies","volume":"50","author":"Duberg","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"R46-20230916","first-page":"w14093","article-title":"Hepatitis C: a changing epidemic","volume":"145","author":"Wandeler","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"R53-20230916","first-page":"147","article-title":"Consensus for the treatment of the chronic hepatitis C in drug-dependent persons in Austria from the view of addiction medicine","volume":"3","author":"Haltmayer","year":"2001","journal-title":"Suchtmedizin Forsch und Prax"},{"key":"R54-20230916","first-page":"C4465","article-title":"Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection: Danish national guidelines 2011","volume":"59","author":"Christensen","year":"2012"},{"key":"R55-20230916","first-page":"501","article-title":"United Kingdom National Guideline on the Management of the Viral Hepatitides A, B & C 2015","volume":"27","year":"2015","journal-title":"Int J STD AIDS"},{"key":"R58-20230916","first-page":"129","article-title":"Guidelines of the German Society of Addiction Medicine (DGS e.V.): therapy of chronic hepatitis C for intravenous drug users","volume":"8","author":"Backmund","year":"2006","journal-title":"Suchtmedizin Forsch und Prax"},{"key":"R59-20230916","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.dld.2010.12.004","article-title":"Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis b and c in special population groups [migrants, intravenous drug users and prison inmates]","volume":"43","author":"Almasio","year":"2011","journal-title":"Dig Liver Dis"},{"key":"R63-20230916","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/23744235.2015.1113438","article-title":"Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus recommendations","volume":"48","author":"Lagging","year":"2016","journal-title":"Infect Dis (Lond)"},{"key":"R68-20230916","first-page":"1817","article-title":"Treatment of drug abuse, current care guideline","volume":"128","author":"Alho","year":"2012","journal-title":"Duodecim"},{"key":"R76-20230916","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/S0168-8278(17)30450-6","article-title":"Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe","volume":"66","author":"Marshall","year":"2017","journal-title":"J Hepatol"},{"key":"R77-20230916","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000320287","article-title":"Liquid drugs and high dead space syringes may keep HIV and HCV prevalence high \u2013 a comparison of Hungary and Lithuania","volume":"16","author":"Gyarmathy","year":"2010","journal-title":"Eur Addict Res"},{"key":"R79-20230916","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugpo.2016.04.007","article-title":"HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: findings from respondent-driven sampling surveys","volume":"32","author":"Handanagic","year":"2016","journal-title":"Int J Drug Policy"},{"key":"R80-20230916","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1186\/1471-2334-14-S6-S6","article-title":"A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia","volume":"14","author":"Maticic","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R82-20230916","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/jech.2006.051599","article-title":"Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis","volume":"62","author":"Vescio","year":"2008","journal-title":"J Epidemiol Community Heal"},{"key":"R84-20230916","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/09687630802227673","article-title":"From margin to mainstream: the evolution of harm reduction responses to problem drug use in Europe","volume":"15","author":"Hedrich","year":"2008","journal-title":"Drugs Educ Prev Policy"},{"key":"R85-20230916","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1360-0443.2011.03676.x","article-title":"The effectiveness of opioid maintenance treatment in prison settings: a systematic review","volume":"107","author":"Hedrich","year":"2012","journal-title":"Addiction"},{"key":"R86-20230916","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-7517-7-17","article-title":"Drug use and opioid substitution treatment for prisoners","volume":"7","author":"St\u00f6ver","year":"2010","journal-title":"Harm Reduct J"},{"key":"R87-20230916","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1477-7517-4-5","article-title":"Substitution treatment for opioid addicts in Germany","volume":"4","author":"Michels","year":"2007","journal-title":"Harm Reduct J"},{"key":"R89-20230916","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10754-012-9119-9","article-title":"Health care utilization by immigrants in Italy","volume":"13","author":"De Luca","year":"2013","journal-title":"Int J Hhealth Care Finance Econ"},{"key":"R90-20230916","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/eurpub\/ckr083","article-title":"Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis","volume":"22","author":"Harris","year":"2012","journal-title":"Eur J Public Health"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042737-201711000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T15:08:38Z","timestamp":1694876918000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042737-201711000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000000962","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}